A meta-analysis: efficacy and safety of anti-epileptic drugs prescribed in Korea as monotherapy and adjunctive treatment for patients with focal epilepsy

JuYeun Jeon, Jaeseong Oh *, and Kyung-Sang Yu

Department of Clinical Pharmacology and Therapeutics, Seoul National University College of Medicine and Hospital, Seoul 03080, Korea

ABSTRACT

Focal epilepsy is the most common type of epilepsy in Korea, and anti-epileptic drugs (AEDs) are the main treatment option for patients. This study aimed to compare the efficacy and safety of AEDs for focal epilepsy through a meta-analysis. The AEDs prescribed in Korea as monotherapy and adjunctive treatment for patients with focal epilepsy were included for analysis. Relevant articles were searched for randomized clinical trials of AEDs and treatment outcomes were analyzed on the basis of the 50% responder rate, seizure-free rate, treatment withdrawal rate, and emergence rates of adverse events (AEs). The odds ratios (ORs) and their 95% confidence intervals (CI) of study outcome were calculated using combined data from multiple studies. A total of 47 studies were included in the meta-analysis. The seizure-free rate, treatment withdrawal rate, and AE rate were not significantly different among the AEDs recommended for monotherapy. Among the AEDs recommended for adjunctive treatment, topiramate and oxcarbazepine yielded the highest OR in comparison with placebo for each efficacy parameter: the 50% responder rate for topiramate = 6.42 (3.76–11.6) and the seizure-free rate for oxcarbazepine = 32.7 (6.05–899). The third-generation AEDs (brivaracetam and perampanel) yielded relatively better safety outcomes than other AEDs. In general, the 50% responder rate and treatment withdrawal rate tended to increase as the dose of the AEDs increased. The results from the current meta-analysis of the efficacy and safety data of various AEDs may provide insight into optimal pharmacotherapy for the treatment of focal epilepsy.

Keywords: Epilepsy; Meta-analysis; Anti-epileptic Drugs; Monotherapy; Adjunctive Treatment

INTRODUCTION

Epilepsy is the fourth most common neurologic disease in the world [1]. It affects around 50 million individuals worldwide and has an annual incidence of approximately 80 cases per 100,000 individuals [2]. Epilepsy makes patients’ daily life uncomfortable, and research has also shown that it increases the risk of developing psychiatric disorders [2]. According to the operational classification of the epilepsy type by the International League Against Epilepsy,
it is classified as focal, generalized, combined, and unknown based on the occurring seizure type [3]. Among the epilepsy types, focal epilepsy accounted for the highest proportion (78.1%); conversely, only 8.0% of patients had been diagnosed with generalized epilepsy, according to an epidemiological study using a nationwide database for Korean patients with epilepsy [4]. Focal epilepsy occurs within networks limited to 1 hemisphere alone, so that when it is well-controlled, patients are expected to lead a normal life and experience an increased quality of life [3].

The treatment options for focal epilepsy are anti-epileptic drugs (AED) administration or surgical intervention [5,6]. Among these options, epilepsy surgery is not preferred in many cases owing to the limited indications and high refusal rate by patients [7,8]. For these reasons, medical treatment with AEDs to suppress seizure occurrence is the common treatment method for patients with focal epilepsy, and approximately two-thirds of the seizures are controlled by these drugs [2,5]. The type of AED to be administered is determined with consideration of its efficacy and safety as well as several other factors, such as electroencephalography findings, medical history, sex, and concomitant medication [5]. However, only a few studies have directly compared the efficacy and safety of various AEDs, which can be useful for the selection of appropriate drugs for patients.

A meta-analysis of published trials can increase the statistical power compared to a single study [9]. Although the safety and efficacy of individual AEDs were identified in clinical trials, the study results are sometimes not consistently reproducible owing to the relatively small sample size [9]. Although there are several medical treatment guidelines for epilepsy, there is limited consensus on the recommended AEDs for the treatment of focal epilepsy (Supplementary Table 1) [5,10-12]. Therefore, the findings of a meta-analysis that can comprehensively compare the efficacy and safety of AEDs can be useful for healthcare professionals to optimize patient care according to the best available evidence.

Based on these findings, this study aimed to compare the efficacy and safety of AEDs that are used as monotherapy and adjunctive treatment for focal epilepsy by performing a meta-analysis of existing clinical trials.

**METHODS**

**Literature search**

The AEDs prescribed in Korea as monotherapy and adjunctive treatment for patients with focal epilepsy were included for analysis (Supplementary Table 1) [5].

To find potentially relevant articles, PubMed, EMBASE, and the Cochrane Library were used. The function “Advanced Search” was utilized with Medical Subject Heading terms. Various drugs (“carbamazepine” or “lamotrigine” or “levetiracetam” or “oxcarbazepine” or “valproate”) and disease term (“epilepsy”) and comparator drug (“monotherapy” or “placebo”) were used to search for monotherapy study results. And various drugs (“brivaracetam” or “carbamazepine” or “clobazam” or “gabapentin” or “lacosamide” or “lamotrigine” or “levetiracetam” or “oxcarbazepine” or “perampanel” or “phenobarbital” or “phenytoin” or “pregabalin” or “rufinamide” or “topiramate” or “valproate” or “vigabatrin” or “zonisamide”) and disease term (“epilepsy”) and comparator drug (“placebo”) were used to search for adjunctive treatment study results. The database search was performed in October.
2019 and March 2020. The title and abstract of all retrieved records were thoroughly screened to identify eligible studies. If there was insufficient information to make a clear judgment by reading an abstract only, the full text was reviewed at the next step. Specific eligibility criteria were applied to select the final suitable articles for the analysis.

**Eligibility criteria**

The inclusion criteria for selecting the eligible studies were as follows: 1) studies using AEDs prescribed in Korea as monotherapy or adjunctive treatment for patients with focal epilepsy; 2) randomized controlled trials with a comparator including placebo; 3) studies with an efficacy endpoint, i.e., seizure-free rate, defined as the proportion of participants who were free from seizure, or 50% responder rate, defined as the proportion of participants with 50% or greater reduction in seizure frequency in the treatment period, compared to that in baseline; 4) studies published in English only; 5) studies on AEDs prescribed in Korea as monotherapy or adjunctive treatment for patients with focal epilepsy. As the number of monotherapy articles for focal epilepsy is limited, the result was included if the number of patients with focal epilepsy was more than half of the total number of subjects when the study subjects included had both focal and generalized epilepsies. 6) journals published after 1990.

Conversely, the exclusion criteria were as follows: 1) studies conducted only for children (younger than 12 years); 2) non-published articles (e.g., conference proceedings and ongoing clinical trials that can be searched at ClinicalTrials.gov only; 3) *in vitro* or animal studies; 4) studies incorporating a surgical intervention or using other therapies that may affect seizure frequency; and 5) cross-over studies.

According to the abovementioned selection criteria, the title, abstract, and full text were carefully reviewed, and only eligible articles were analyzed in this study. Duplicate studies or overlapping cases were removed prior to data extraction. No restriction was imposed on the mode of treatment, such as the dose, route, and duration of administration.

**Data extraction**

Relevant data were extracted from the eligible studies [13-59], and statistical and non-statistical data were retrieved. The following information was considered the non-statistical data: 1) study identification (authors’ name and year of publication) and 2) intervention information (drug names and duration). The following relevant information on efficacy was considered the statistical data and used as efficacy endpoints; 3) responder rate: the proportion of the number of patients with ≥ 50% reduction in seizure frequency compared with the baseline per arm; 4) seizure-free rate: the proportion of the number of patients free from seizure per arm for designated period according to each study design. The following safety relevant statistical or non-statistical data was extracted and used as safety endpoints; 5) withdrawal rate: the proportion of the number of patients who discontinued the treatment owing to adverse events (AEs); 6) AE rate: the proportion of the number of patients experiencing at least one AE per arm regardless of relevance with AEDs; and 7) common AE: AEs reported in more than 10% of subjects in total in each AED group.

For studies that reported their results as the proportion of responders only, the ratio was converted into the number of patients through calculation. When a graph or table was available to reveal the efficacy results solely, values were taken from them directly. When such data were not provided even in the table or figure, narrative information was closely reviewed.
to extract the necessary data. If multiple publications were searched for the same trial, data were extracted from a single article among them.

To perform a sub-analysis for the 50% responder rate and treatment withdrawal rate owing to AEs, we separately obtained the number of responders and non-responders at each dose level when there were multiple dose levels in the same treatment arm. To calculate the odds ratios (ORs), we evenly divided the total number of patients and responders in the placebo arm against the respective dose of the treatment arm. The number of patients and the number of responders were combined according to the dose strength among the different studies to assess the total effect size at each dose level. Studies that did not reveal the efficacy by dose were excluded from the sub-analysis.

**Quality assessment**
The Preferred Reporting Items for Systematic Reviews and Meta-analyses were implemented in this meta-analysis [60]. The methodological quality of this study was assessed using the Assessment of Multiple Systematic Reviews (AMSTAR) tool, which was developed to evaluate systematic reviews of randomized trials [61,62]. The risk of bias was evaluated to ensure the quality of the selected articles.

**Statistical analysis**
The study used Bayesian network meta-analysis for monotherapy and indirect comparisons for adjunctive treatment to assess the efficacy and safety of each AED. For monotherapy, carbamazepine was set as a comparator drug, as it was one of the commonly prescribed first-line drugs for focal epilepsy [63]. Owing to the different scales across the studies, the ORs and their 95% confidence intervals (CI) of efficacy and safety outcome were calculated using combined data from multiple studies, based on the fixed effect model or random effect model to the standardized effect size. The 95% CI was used to gauge the clinical benefit of the treatment compared with the control. R software (Version 3.6.1) was applied, and the R commands for statistical analysis are described in Supplementary Fig. 1. Statistical heterogeneity was tested using the magnitude of heterogeneity quantified by calculating a point estimate of the among-study variance of true effects ($\tau^2$) and the percentage of total variation across studies owing to heterogeneity rather than sampling error ($I^2$) [64]. The fixed effect model was used when heterogeneity was negative ($p \geq 0.05$) and the random effect model in the opposite case ($p < 0.05$). A publication bias test is required when more than 10 studies are involved for analysis in each treatment group; thus, the test was not applicable in this study [65].

**Ethics statement**
As this meta-analysis was based on existing studies, Institutional Review Board approval was not necessary.

**RESULTS**

**Search results**
A total of 1,929 relevant records were searched from the 3 databases, and 1,164 articles were identified after excluding duplicate studies. After exclusion of ineligible publications, a total of 47 studies (10 direct comparison articles for monotherapy and 37 articles for placebo control as an adjunctive treatment) were included for data analysis (Fig. 1). With regard to
the adjunctive treatment study of clobazam, phenobarbital, and phenytoin, there were no adequate articles that satisfied the eligibility criteria; thus, they were not included in this meta-analysis. The detailed characteristics of the included studies are shown in Table 1.

**Efficacy endpoint**

**Responder rate**

In monotherapy, all 10 selected articles did not report the responder rate as the efficacy endpoint.

In adjunctive treatment, the 50% responder rate was significantly higher in all AED groups than in the placebo group, except for levetiracetam (Fig. 2). Topiramate yielded the highest responder rate among the adjunctive treatment (OR, 6.42 [95% CI, 3.76-11.6]). The responder rate for topiramate was based on 5 trials and statistically significant highest OR. The ORs for oxcarbazepine, pregabalin, zonisamide, vigabatrin, gabapentin, perampanel, brivaracetam, and rufinamide were more than 2; the results were pooled from at least 3 trials, except for oxcarbazepine, vigabatrin, and lamotrigine, which were calculated from only 1, 1, and 2 trials, respectively.

**Seizure-free rate**

In monotherapy, of 10 monotherapy studies, 8 studies and 7 studies assessed 6- and 12-month seizure-free events, respectively. Seizure-free rates were not statistically different (Fig. 3).

In adjunctive treatment, the seizure-free rates were higher for the AEDs, except for topiramate, than for the placebo (Fig. 2). No seizure-free rate was reported for topiramate in both arms; however, this was obtained from only 1 study performed in a small number of patients (30 patients in each treatment arm), so it was not visualized in Fig. 2. The OR was insignificantly higher for lacosamide, rufinamide, and zonisamide than for placebo. The highest seizure-free rate was observed for oxcarbazepine (OR, 32.7; 95% CI, 6.05–899).

**Safety endpoints**

**Withdrawal rate**

In monotherapy, the withdrawal rate owing to AEs compared to carbamazepine was not also statistically significant (Fig. 3).

In adjunctive treatment, the treatment withdrawal rate owing to AEs was generally higher for the AEDs (OR is greater than 1) than for the placebo, but was not significant for vigabatrin.
and levetiracetam (Fig. 2). The treatment withdrawal rate owing to AEs for the third-generation AEDs was low, except for rufinamide (OR, 3.42; 95% CI, 1.96–6.08). At least 1 trial from each AED group reported a treatment withdrawal rate owing to AEs.

Total AEs
In monotherapy, emergence rate of AEs was not statistically significant (Fig. 3).
Anti-epileptic drugs as treatment for focal epilepsy

A 50% responder rate

| Drug                  | OR (95% CI)         | Compared with placebo |
|-----------------------|---------------------|-----------------------|
| Brivaracetam          | 2.08 (1.66–2.64)    |                       |
| Gabapentin            | 2.61 (1.45–4.78)    |                       |
| Lacosamide            | 1.90 (1.37–2.63)    |                       |
| Lamotrigine           | 1.65 (1.11–2.43)    |                       |
| Levetiracetam         | 1.83 (0.956–3.48)   |                       |
| Oxcarbazepine         | 4.52 (2.88–7.59)    |                       |
| Perampanel            | 2.13 (1.69–2.71)    |                       |
| Pregabalin            | 2.77 (2.17–3.54)    |                       |
| Rufinamide            | 2.04 (1.49–2.87)    |                       |
| Topiramate            | 6.42 (3.76–11.6)    |                       |
| Vigabatrin            | 2.66 (1.25–6.08)    |                       |
| Zonisamide            | 2.76 (1.90–3.97)    |                       |

B Seizure free rate

| Drug                  | OR (95% CI)         | Compared with placebo |
|-----------------------|---------------------|-----------------------|
| Brivaracetam          | 8.39 (2.97–26.9)    |                       |
| Lacosamide            | 2.50 (0.776–11.7)   |                       |
| Lamotrigine           | 2.06 (1.19–3.71)    |                       |
| Levetiracetam         | 12.2 (1.78–321)     |                       |
| Oxcarbazepine         | 32.7 (6.05–899)     |                       |
| Perampanel            | 5.10 (1.82–22.4)    |                       |
| Pregabalin            | 1.69 (1.01–2.84)    |                       |
| Rufinamide            | 1.15 (0.372–3.48)   |                       |
| Zonisamide            | 3.99 (0.417–126)    |                       |

C Withdrawal rate

| Drug                  | OR (95% CI)         | Compared with placebo |
|-----------------------|---------------------|-----------------------|
| Brivaracetam          | 1.72 (1.12–2.89)    |                       |
| Gabapentin            | 4.72 (1.21–36.1)    |                       |
| Lacosamide            | 3.18 (1.83–6.05)    |                       |
| Lamotrigine           | 3.61 (1.88–7.34)    |                       |
| Levetiracetam         | 2.95 (0.553–24.3)   |                       |
| Oxcarbazepine         | 6.69 (3.99–12.3)    |                       |
| Perampanel            | 2.10 (1.36–3.35)    |                       |
| Pregabalin            | 2.92 (2.06–4.33)    |                       |
| Rufinamide            | 3.42 (1.96–6.08)    |                       |
| Topiramate            | 3.71 (1.86–8.26)    |                       |
| Vigabatrin            | 1.45 (0.370–6.05)   |                       |
| Zonisamide            | 3.73 (1.85–8.56)    |                       |

D Adverse events rate

| Drug                  | OR (95% CI)         | Compared with placebo |
|-----------------------|---------------------|-----------------------|
| Brivaracetam          | 1.27 (1.03–1.57)    |                       |
| Gabapentin            | 2.48 (1.63–3.79)    |                       |
| Lacosamide            | 2.28 (1.31–3.86)    |                       |
| Lamotrigine           | 1.34 (0.789–2.31)   |                       |
| Levetiracetam         | 0.901 (0.478–1.70)  |                       |
| Oxcarbazepine         | 3.04 (1.95–4.78)    |                       |
| Perampanel            | 1.61 (1.29–2.00)    |                       |
| Pregabalin            | 1.83 (1.40–2.36)    |                       |
| Rufinamide            | 1.59 (1.20–2.12)    |                       |
| Zonisamide            | 1.78 (1.24–2.57)    |                       |

Figure 2. OR for adjunctive treatment for the 50% responder, seizure-free rate, withdrawal rate, and adverse event rates when compared with placebo. OR, odds ratio; CI, confidence interval.

A 6-month seizure free

| Drug      | OR (95% CI)       | Compared with carbamazepine |
|-----------|-------------------|-----------------------------|
| Lamotrigine| 0.998 (0.764–1.33) |                             |
| Levetiracetam | 0.919 (0.755–1.12) |                             |
| Oxcarbazepine | 0.883 (0.471–1.71) |                             |
| Valproate  | 0.816 (0.394–1.71) |                             |

B 12-month seizure free

| Drug      | OR (95% CI)       | Compared with carbamazepine |
|-----------|-------------------|-----------------------------|
| Lamotrigine| 0.814 (0.570–1.16) |                             |
| Levetiracetam | 0.850 (0.695–1.04) |                             |
| Oxcarbazepine | 0.994 (0.573–1.72) |                             |
| Valproate  | 0.803 (0.504–1.30) |                             |

C Withdrawal rate

| Drug      | OR (95% CI)       | Compared with carbamazepine |
|-----------|-------------------|-----------------------------|
| Lamotrigine| 0.485 (0.343–0.673)|                             |
| Levetiracetam | 0.569 (0.451–0.718)|                             |
| Oxcarbazepine | 1.090 (0.496–2.50)|                             |
| Valproate  | 0.679 (0.454–0.995)|                             |

D Adverse events rate

| Drug      | OR (95% CI)       | Compared with carbamazepine |
|-----------|-------------------|-----------------------------|
| Lamotrigine| 0.820 (0.561–1.20)|                             |
| Levetiracetam | 0.971 (0.784–1.20)|                             |
| Oxcarbazepine | 1.280 (0.784–2.18)|                             |
| Valproate  | 0.814 (0.554–1.19)|                             |

Figure 3. OR for monotherapy for the 6- and 12-month seizure-free, withdrawal rate, and adverse event rates when compared with carbamazepine. OR, odds ratio; CI, confidence interval.

In adjunctive treatment, except for levetiracetam, the emergence rates of the AEs were generally higher for the AEDs than for the placebo; however, this finding was not significant for lamotrigine (Fig. 2). For levetiracetam, only one trial was analyzed, and the AE rate was lower than with placebo. For all other AEDs, there was a greater AE rate with the studied drug compared with placebo.
slightly higher in the placebo arm. The emergence rates of the AEs were relatively lower for the third-generation AEDs. In general, the drugs associated with a high incidence of AEs yielded a high treatment withdrawal rate.

**Frequently observed AEs**

The frequently reported AEs, which were reported in more than 10% of patients, were headache, dizziness and somnolence, fatigue, and nausea (Tables 2 and 3). Eye-related disorders, such as diplopia, nystagmus, and blurred/abnormal vision, were observed in patients treated with oxcarbazepine, topiramate, and vigabatrin. Weight increase was a frequently reported AE in patients treated with vigabatrin and pregabalin. We could not identify the safety profile of valproate from the searched articles.

**Sub-analysis results according to the dose levels of each AED**

Dose-response analysis of the selected efficacy and safety item for adjunctive treatment was performed. In general, the 50% responder rate tended to increase as the dose of the AEDs increased within the same treatment group. (Fig. 4). In addition, the treatment withdrawal rate owing to AEs tended to increase as the dose of the AEDs increased, except for brivaracetam (Fig. 5).

**Quality assessment**

In general, the methodological quality of this meta-analysis, which was assessed using the AMSTAR tool, did not have a significant bias. In the review results, 14 items out of the

---

**Table 2. Summary of commonly reported adverse events associated with anti-epileptic drugs recommended as monotherapy**

| Adverse events | Carbamazepine (n = 1,040) | Lamotrigine (n = 1,073) | Levetiracetam (n = 1,273) | Oxcarbazepine (n = 174) |
|----------------|--------------------------|-------------------------|--------------------------|------------------------|
| Headache       | 137 (13.1)               | 129 (12.4)              | 263 (20.7)               | 20 (11.5)              |
| Fatigue        | 219 (17.5)               | 69 (12.8)               | 219 (17.2)               | -                      |
| Dizziness      | 147 (14.1)               | 56 (10.4)               | 138 (10.8)               | 37 (21.3)              |
| Nausea         | 106 (10.2)               | 64 (11.9)               | -                        | -                      |
| Somnolence     | -                        | -                       | 18 (10.3)                |                        |

Data in bracket are presented as the percentage of subjects who experienced at least 1 adverse event among the total number of subjects.

**Table 3. Summary of commonly reported adverse events associated with anti-epileptic drugs recommended as adjunctive treatment**

| Adverse events | GBP (n = 335) | TPM (n = 359) | LCM (n = 643) | VGB (n = 58) | ZSM (n = 352) | LMT (n = 118) | LEV (n = 77) | OXC (n = 519) | PGB (n = 1,391) | BRV (n = 1,204) | PER (n = 1,709) | RFA (n = 871) |
|----------------|---------------|---------------|---------------|-------------|--------------|---------------|-------------|--------------|----------------|----------------|---------------|--------------|
| Headache       | 138 (39.8)    | 143 (39.8)    | 83 (12.9)     | 19 (32.8)   | 20 (16.9)    | -             | 142 (27.4)  | -            | 120 (10.0)     | -              | 191 (21.9)    |              |
| Fatigue        | -             | 113 (31.5)    | -             | 15 (25.9)   | 72 (13.9)    | -             | -           | -            | 153 (17.6)     | -              | -             |              |
| Dizziness      | 72 (21.3)     | 168 (46.8)    | 112 (17.4)    | 13 (22.4)   | 72 (13.9)    | -             | -           | -            | 172 (33.1)     | 367 (26.4)     | 128 (10.6)    | 494 (28.9)   |
| Nausea         | -             | -             | 68 (10.6)     | -           | -            | -             | -           | -            | 1177 (22.2)    | -              | 106 (21.2)    |              |
| Somnolence     | 113 (33.7)    | 138 (38.4)    | 73 (11.4)     | 10 (17.2)   | -            | -             | 137 (26.4)  | 920 (15.8)   | 166 (13.8)     | 261 (15.3)     | 101 (11.6)    |              |
| Diplopia       | -             | 68 (18.9)     | -             | -           | -            | 145 (27.9)    | -           | -            | -              | -              | -             |              |
| Ataxia         | 42 (12.5)     | 100 (27.9)    | -             | 7 (12.1)    | -            | -             | 103 (19.8)  | -            | -              | -              | -             |              |
| Nystagmus      | 81 (22.6)     | -             | -             | -           | -            | 88 (17)       | -           | -            | -              | -              | -             |              |
| Blurred/abnormal vision | -       | -             | 8 (13.8)     | -           | -            | 65 (12.5)     | -           | -            | -              | -              | -             |              |
| Thinking differently | -     | 118 (32.9)   | -             | -           | -            | -             | -           | -            | -              | -              | -             |              |
| Increased weight | -        | -             | 7 (12.1)     | -           | -            | -             | 153 (11.0)  | -            | -              | -              | -             |              |
| Confusion      | -             | 41 (11.4)     | -             | -           | -            | -             | -           | -            | -              | -              | -             |              |

Data in bracket are presented as the percentage of subjects who experienced at least 1 adverse event among the total number of subjects.

GBP, gabapentin; TPM, topiramate; LCM, lacosamide; VGB, vigabatrin; ZSM, zonisamide; LMT, lamotrigine; LEV, levetiracetam; OXC, oxcarbazepine; PGB, pregabalin; BRV, brivaracetam; PER, perampanel; RFA, rufinamide.
16 questions were satisfied and rated as moderate at overall confidence. Although 2 items required review from the second reviewer, we selected articles according to the pre-selected inclusion and exclusion criteria to ensure fairness and verified the extracted data thrice to ensure accuracy. All of the clinical trials included in this meta-analysis could be rated as having a low risk of detection bias. Each trial had a double-blind study design, and the study results were disclosed by publishing articles to the journals. The study outcome was measured using the same methods between the intervention groups.

**DISCUSSION**

In this study, the total effect size for various AEDs was analyzed on the basis of efficacy and safety parameters for each drug, and the results can be useful for healthcare professionals, as the current epilepsy treatment guidelines suggest only some lists of recommended AEDs. Although the safety and efficacy profiles of each AED can be identified from individual study results, some of the individual trials lack efficacy or safety data, which limits the comprehensive understanding of specific drugs. This study obtained efficacy and safety data from several clinical trials and consolidated them based on the same endpoints to compare
the efficacy and safety profiles of various AEDs. In addition, we provided the relative effect size weighted by the sample size to avoid bias caused by the different sample sizes of each study. Furthermore, this study focused on the AEDs prescribed in Korea for patients with focal epilepsy; therefore, our study results can provide practical information for epilepsy treatment in Korea.

In this study, a Bayesian network meta-analysis was used to compare the relative efficacy among AEDs for monotherapy. It was impossible to use a placebo as a comparator drug in the studies for AEDs recommended as monotherapy owing to ethical and safety considerations. These studies did not include common comparator drugs; therefore, it was not easy to calculate the relative efficacy among the AEDs using other meta-analysis methods. The analysis method used in this meta-analysis was appropriate to generate the relative OR for each AED based on direct comparison from individual trials.

The guidelines by the Korean Epilepsy Society suggested carbamazepine as the first choice among the suggested AEDs for monotherapy. Carbamazepine showed statistically insignificant better OR for both the 6- and 12-month seizure-free rates among the AEDs recommended as monotherapy (Fig. 3). Further, topiramate showed the highest OR for the 50% responder rate among the AEDs recommended as adjunctive treatment, which corresponds to a previous meta-analysis result [66]. Oxcarbazepine, perampanel, lamotrigine, and brivaracetam revealed significantly higher ORs than did placebo for both 50% responder rate and seizure-free rate.

In this study, safety and tolerability were evaluated on the basis of the treatment withdrawal rate owing to AEs and the proportion of subjects who experienced AEs. The drugs with low withdrawal rates yielded a low incidence of AEs. Among the AEDs recommended as monotherapy, the difference was not significant in terms of treatment withdrawal rate owing to AEs and AE emergence rate (Fig. 3). Among the AEDs recommended as adjunctive treatment, oxcarbazepine yielded the highest withdrawal rate and AE rate; therefore, careful monitoring of drug safety is needed when using oxcarbazepine (Fig. 2). The results of safety assessment about frequent AEs reported from over 10% of patients, headache, dizziness, somnolence, fatigue, and nausea corresponds to a previous meta-analysis result [67]. Eye-related disorders were reported as AEs when treated with oxcarbazepine, topiramate, and vigabatrin and it was aligned with the result from the previous study and guideline by Korean Epilepsy Society [5,68].

The third-generation AEDs showed a relatively better safety profile than did the other drugs (Fig. 2).

The sub-analysis, which was performed according to the dose levels, revealed an increasing tendency of the efficacy and safety parameters (50% responder rate and treatment withdrawal rate owing to AEs, respectively) as the dose of each AED increased (Figs. 4 and 5). The dose-response relationship explored in this study can add additional information that can be used for optimal pharmacotherapy for patients with focal epilepsy. This information can also be useful when adjusting the dose during pharmacotherapy of patients with focal epilepsy.

The study has some limitations. Most of the clinical trials enrolled for this analysis were conducted in non-Korean population. It appears that the studies of monotherapy for focal epilepsy also included the trials that enrolled both patient groups, focal and generalized
epilepsies. Some of the study findings were driven from the results from a small number of clinical trials. For example, the oxcarbazepine showed highest seizure-free rate when used for adjunctive treatment. However, that result should be interpreted with some caution as that finding was driven from only one clinical trial.

Despite all of these limitations, the results of the meta-analysis would be an updated knowledge of focal epilepsy treatment in Korea. This study compared the efficacy and safety of various AEDs used for the treatment of focal epilepsy by performing a meta-analysis, and the results can be useful for optimal pharmacotherapy for patients with focal epilepsy.

ACKNOWLEDGMENTS

We would like to thank investigators who performed the trials included in this article for meta-analysis to generate total efficacy and safety.

SUPPLEMENTARY MATERIALS

Supplementary Table 1
Clinical guideline for anti-epileptic drugs treatment in patients with epilepsy

Click here to view

Supplementary Fig. 1
R scripts and R commands using the “gemtc” package in R software, version 3.6.1 for meta-analysis, using the number of patients who responded and total number of patients who were involved for analysis in the experimental group versus control group.

Click here to view

REFERENCES

1. Epilepsy Foundation. What is epilepsy? https://www.epilepsy.com/learn/about-epilepsy-basics/what-epilepsy. Updated 2014. Accessed December 22, 2019.
2. World Health Organization. Epilepsy. https://www.who.int/news-room/fact-sheets/detail/epilepsy. Updated 2019. Accessed December 22, 2019.
3. Fisher RS, Cross JH, French JA, Higurashi N, Hirsch E, Jansen FE, et al. Operational classification of seizure types by the International League Against Epilepsy: position paper of the ILAE Commission for Classification and Terminology. Epilepsia 2017;58:522-530.
4. Jeong KY. Epidemiological study of seizure and epilepsy using nationwide database for Korean epilepsy patients (ESSENCE). Seoul: Korean Epilepsy Society; 2012.
5. Kim KK, Kim KJ, Bae EK, Yoon CH, Lee SK, Hong SH. Clinical guideline for antiepileptic drug treatment in patient with epilepsy. Seoul: Korean Epilepsy Society; 2015.
6. Jobst BC, Cascino GD. Resective epilepsy surgery for drug-resistant focal epilepsy: a review. JAMA 2015;313:285-293.
7. Rathore C, Radhakrishnan K. Concept of epilepsy surgery and presurgical evaluation. Epileptic Disord 2015;17:19-31.
8. Ladino LD, Benjumea-Cuartas V, Diaz-Marin DM, Lopez-Gonzalez R, Orozco-Hernandez JP, Bedoya-Rodriguez P, et al. Patients' perceptions of and attitudes towards epilepsy surgery: mistaken concepts in Colombia. Rev Neurol 2018;67:6-14.
PUBMED

9. Lee YH. An overview of meta-analysis for clinicians. Korean J Intern Med 2018;33:277-283.
PUBMED | CROSSREF

10. Kanner AM, Ashman E, Gloss D, Harden C, Bourgeois B, Bautista JF, et al. Practice guideline update summary: efficacy and tolerability of the new antiepileptic drugs I: treatment of new-onset epilepsy: report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology and the American Epilepsy Society. Neurology 2018;91:74-81.
PUBMED | CROSSREF

11. Shih JJ, Whitlock JB, Chimato N, Vargas E, Karczewski SC, Frank RD. Epilepsy treatment in adults and adolescents: expert opinion, 2016. Epilepsy Behav 2017;69:186-222.
PUBMED | CROSSREF

12. The National Institute for Health and Care Excellence (NICE). Epilepsies: diagnosis and management. https://www.nice.org.uk/guidance/cg137/chapter/1-guidance. Updated February 11, 2020. Accessed June 2020.

13. Brodie MJ, Perucca E, Ryvlin P, Ben-Menachem E, Meencke HJ. Levetiracetam Monotherapy Study Group. Comparison of levetiracetam and controlled-release carbamazepine in newly diagnosed epilepsy. Neurology 2007;68:402-408.
PUBMED | CROSSREF

14. Kim JH, Lee SK, Loesch C, Namgoong K, Lee HW, Hong SB, et al. Comparison of levetiracetam and oxcarbazepine monotherapy among Korean patients with newly diagnosed focal epilepsy: a long-term, randomized, open-label trial. Epilepsia 2017;58:e70-e74.
PUBMED | CROSSREF

15. Brodie MJ, Richens A, Yuen AWU. Lamotrigine/Carbamazepine Monotherapy Trial Group. Double-blind comparison of lamotrigine and carbamazepine in newly diagnosed epilepsy. Lancet 1995;345:476-479.
PUBMED | CROSSREF

16. Trinka E, Marson AG, Van Paesschen W, Kälviäinen R, Marovac J, Duncan B, et al. KOMET: an unblinded, randomised, two parallel-group, stratified trial comparing the effectiveness of levetiracetam with controlled-release carbamazepine and extended-release sodium valproate as monotherapy in patients with newly diagnosed epilepsy. J Neurol Neurosurg Psychiatry 2013;84:1138-1147.
PUBMED | CROSSREF

17. Heller AJ, Chesterman P, Elwes RD, Crawford P, Chadwick D, Johnson AL, et al. Phenobarbitone, phenytoin, carbamazepine, or sodium valproate for newly diagnosed adult epilepsy: a randomised comparative monotherapy trial. J Neurol Neurosurg Psychiatry 1995;58:44-50.
PUBMED | CROSSREF

18. Rosenow F, Schade-Brittinger C, Burchardi N, Bauer S, Klein KM, Weber Y, et al. The LaLiMo Trial: lamotrigine compared with levetiracetam in the initial 26 weeks of monotherapy for focal and generalised epilepsy--an open-label, prospective, randomised controlled multicenter study. J Neurol Neurosurg Psychiatry 2012;83:1093-1098.
PUBMED | CROSSREF

19. Stephen LJ, Sills GJ, Leach JP, Butler E, Parker P, Hitiris N, et al. Sodium valproate versus lamotrigine: a randomised comparison of efficacy, tolerability and effects on circulating androgenic hormones in newly diagnosed epilepsy. Epilepsy Res 2007;75:122-129.
PUBMED | CROSSREF

20. Werhahn KJ, Trinka E, Dobesberger J, Unterberger I, Baum P, Deckert-Schmitz M, et al. A randomized, double-blind comparison of antiepileptic drug treatment in the elderly with new-onset focal epilepsy. Epilepsia 2015;56:450-459.
PUBMED | CROSSREF

21. Steinhoff BJ, Ueberall MA, Siemes H, Kurlemann G, Schmitz B, Bergmann L, et al. The LAM-SAFE Study: lamotrigine versus carbamazepine or valproic acid in newly diagnosed focal and generalised epilepsies in adolescents and adults. Seizure 2005;14:597-605.
PUBMED | CROSSREF

22. Privitera MD, Brodie MJ, Mattsson RH, Chadwick DW, Neto W, Wang S, et al. Topiramate, carbamazepine and valproate monotherapy: double-blind comparison in newly diagnosed epilepsy. Acta Neurol Scand 2003;107:165-175.
PUBMED | CROSSREF

23. Sivenius J, Kälviäinen R, Ylinen A, Riekkinen P. Double-blind study of Gabapentin in the treatment of partial seizures. Epilepsia 1991;32:539-542.
PUBMED | CROSSREF
24. Yamauchi T, Kaneko S, Yagi K, Sase S. Treatment of partial seizures with gabapentin: double-blind, placebo-controlled, parallel-group study. Psychiatry Clin Neurosci 2006;60:507-515.

25. The US Gabapentin Study Group No. 5. Gabapentin as add-on therapy in refractory partial epilepsy: a double-blind, placebo-controlled, parallel-group study. Neurology 1993;43:2292-2298.

26. Naritoku DK, Warnock CR, Messenheimer JA, Borgohain R, Evers S, Guekht AB, et al. Lamotrigine extended-release as adjunctive therapy for partial seizures. Neurology 2007;69:1610-1618.

27. Baulac M, Leon T, O'Brien TJ, Whalen E, Barrett J. A comparison of pregabalin, lamotrigine, and placebo as adjunctive therapy in patients with refractory partial-onset seizures. Epilepsy Res 2010;91:10-19.

28. Peltoja J, Coetzee C, Jiménez F, Litovchenko T, Ramaratnam S, Zaslavskiy L, et al. Once-daily extended-release levetiracetam as adjunctive treatment of partial-onset seizures in patients with epilepsy: a double-blind, randomized, placebo-controlled trial. Epilepsia 2009;50:406-414.

29. Barcs G, Walker EB, Elger CE, Scaramelli A, Stafán H, Sturm Y, et al. Oxcarbazepine placebo-controlled, dose-ranging trial in refractory partial epilepsy. Epilepsia 2000;41:1597-1607.

30. Privitera M, Fincham R, Penny J, Reife R, Kramer L, Pledger G, et al. Topiramate placebo-controlled dose-ranging trial in refractory partial epilepsy using 600-, 800-, and 1,000-mg daily dosages. Neurology 1996;46:1678-1683.

31. Sharief M, Viteri C, Ben-Menachem E, Weber M, Reife R, Pledger G, et al. Double-blind, placebo-controlled study of topiramate in patients with refractory partial epilepsy. Epilepsy Res 1996;25:217-224.

32. Faught E, Wilder BJ, Ramsay RE, Reife RA, Kramer LD, Pledger GW, et al. Topiramate placebo-controlled dose-ranging trial in refractory partial epilepsy using 200-, 400-, and 600-mg daily dosages. Neurology 1996;46:1684-1690.

33. Ben-Menachem E, Henriksen O, Dam M, Mikkelsen M, Schmidt D, Reid S, et al. Double-blind, placebo-controlled trial of topiramate as add-on therapy in patients with refractory partial seizures. Epilepsia 1996;37:539-543.

34. Tassinari CA, Michelucci R, Chauvel P, Chodkiewicz J, Shorvon S, Henriksen O, et al. Double-blind, placebo-controlled trial of topiramate (600 mg daily) for the treatment of partial seizures. Epilepsia 1996;37:763-768.

35. Ben-Menachem E, Biton V, Jatuzis D, Abou-Khalil B, Doty P, Rudd GD. Efficacy and safety of oral lacosamide as adjunctive therapy in adults with partial-onset seizures. Epilepsia 2007;48:1308-1317.

36. Halász P, Káviária R, Mazarikiewicz-Beldzińska M, Rosenow F, Doty P, Hebert D, et al. Adjunctive lacosamide for partial-onset seizures: efficacy and safety results from a randomized controlled trial. Epilepsia 2009;50:443-453.

37. French JA, Brandt C, Friedman D, Biton V, Knapp L, Pitman V, et al. Adjunctive use of controlled-release pregabalin in adults with treatment-resistant partial seizures: a double-blind, randomized, placebo-controlled trial. Epilepsia 2014;55:1220-1228.
41. Arroyo S, Anhut H, Kugler AR, Lee CM, Knapp LE, Garofalo EA, et al. Pregabalin add-on treatment: a randomized, double-blind, placebo-controlled, dose-response study in adults with partial seizures. Epilepsia 2004;45:20-27. PubMed | CrossRef

42. Bruni J, Guberman A, Vachon L, Desforges C The Canadian Vigabatrin Study Group. Vigabatrin as add-on therapy for adult complex partial seizures: a double-blind, placebo-controlled multicentre study. Seizure 2000;9:224-232. PubMed | CrossRef

43. Lu Y, Xiao Z, Yu W, Xiao F, Xiao Z, Hu Y, et al. Efficacy and safety of adjunctive zonisamide in adult patients with refractory partial-onset epilepsy: a randomized, double-blind, placebo-controlled trial. Clin Drug Investig 2011;31:221-229. PubMed | CrossRef

44. Schmidt D, Jacob R, Loiseau P, Deisenhammer E, Klinger D, Despland A, et al. Zonisamide for add-on treatment of refractory partial epilepsy a European double-blind trial. Epilepsy Res 1993;15:67-73. PubMed | CrossRef

45. Brodie MJ, Duncan R, Vespignani H, Solyom A, Bitenskyy V, Lucas C. Dose-dependent safety and efficacy of zonisamide: a randomized, double-blind, placebo-controlled study in patients with refractory partial seizures. Epilepsia 2005;46:31-41. PubMed | CrossRef

46. Sackellares JC, Ramsay RE, Wilder BJ, Browne TR 3rd, Shellenberger MK. Randomized, controlled clinical trial of zonisamide as adjunctive treatment for refractory partial seizures. Epilepsia 2004;45:610-617. PubMed | CrossRef

47. Kwan P, Trinka E, Van Paesschen W, Rektor I, Johnson ME, Lu S. Adjunctive brivaracetam for uncontrolled focal and generalized epilepsies: results of a phase III, double-blind, randomized, placebo-controlled, flexible-dose trial. Epilepsia 2014;55:38-46. PubMed | CrossRef

48. Ryvlin P, Werhahn KJ, Blasczcyk B, Johnson ME, Lu S. Adjunctive brivaracetam in adults with uncontrolled focal epilepsy: results from a double-blind, randomized, placebo-controlled trial. Epilepsia 2014;55:47-56. PubMed | CrossRef

49. Biton V, Berkovic SF, Abou-Khalil B, Sperling MR, Johnson ME, Lu S. Brivaracetam as adjunctive treatment for uncontrolled partial epilepsy in adults: a phase III randomized, double-blind, placebo-controlled trial. Epilepsia 2014;55:57-66. PubMed | CrossRef

50. Van Paesschen W, Hirsch E, Johnson M, Falter U, von Rosenstiel P. Efficacy and tolerability of adjunctive brivaracetam in adults with uncontrolled partial-onset seizures: a phase IIb, randomized, controlled trial. Epilepsia 2013;54:89-97. PubMed | CrossRef

51. Klein P, Schiemann J, Sperling MR, Whitesides J, Liang W, Stalvey T, et al. A randomized, double-blind, placebo-controlled, multicenter, parallel-group study to evaluate the efficacy and safety of adjunctive brivaracetam in adult patients with uncontrolled partial-onset seizures. Epilepsia 2015;56:1890-1898. PubMed | CrossRef

52. Elger CE, Stefan H, Mann A, Narurkar M, Sun Y, Perdomo C. A 24-week multicenter, randomized, double-blind, parallel-group, dose-ranging study of rufinamide in adults and adolescents with inadequately controlled partial seizures. Epilepsy Res 2010;88:255-263. PubMed | CrossRef

53. Pålhagen S, Canger R, Henriksen O, van Parys JA, Riviére ME, Karolchyk MA. Rufinamide: a double-blind, placebo-controlled proof of principle trial in patients with epilepsy. Epilepsia Res 2001;43:115-124. PubMed | CrossRef

54. Biton V, Krauss G, Vasquez-Santana B, Bibbiani F, Mann A, Perdomo C, et al. A randomized, double-blind, placebo-controlled, parallel-group study of rufinamide as adjunctive therapy for refractory partial-onset seizures. Epilepsia 2011;52:234-242. PubMed

55. Brodie MJ, Rosenfeld WE, Vazquez B, Sachdeo R, Perdomo C, Mann A, et al. Rufinamide for the adjunctive treatment of partial seizures in adults and adolescents: a randomized placebo-controlled trial. Epilepsia 2009;50:1899-1909. PubMed | CrossRef

56. Krauss GL, Bar M, Biton V, Klapper JA, Rektor I, Vaicenie-Magistris N, et al. Tolerability and safety of perampanel: two randomized dose-escalation studies. Acta Neurol Scand 2012;125:8-15. PubMed | CrossRef

https://tcp Pharm.org

https://doi.org/10.12793/tcp.2021.29.e1
57. French JA, Krauss GL, Biton V, Squillacote D, Yang H, Laurenza A, et al. Adjunctive perampanel for refractory partial-onset seizures: randomized phase III study 304. Neurology 2012;79:589-596.

58. Nishida T, Lee SK, Inoue Y, Saeki K, Ishikawa K, Kaneko S. Adjunctive perampanel in partial-onset seizures: Asia-Pacific, randomized phase III study. Acta Neurol Scand 2018;137:392-399.

59. Krauss GL, Serratosa JM, Villanueva V, Endziniene M, Hong Z, French J, et al. Randomized phase III study 306: adjunctive perampanel for refractory partial-onset seizures. Neurology 2012;78:1408-1415.

60. PRISMA. Preferred reporting items for systematic reviews and meta-analysis (PRISMA). http://www.prisma-statement.org/. Updated 2015. Accessed December 25, 2019.

61. Assessing the Methodological Quality of Systematic Reviews. AMSTAR checklist. https://amstar.ca/Amstar_Checklist.php. Updated 2017. Accessed December 25, 2019.

62. Shea BJ, Reeves BC, Wells G, Thuku M, Hamel C, Moran J, et al. AMSTAR 2: a critical appraisal tool for systematic reviews that include randomised or non-randomised studies of healthcare interventions, or both. BMJ 2017;358:j4008.

63. Legros B, Boon P, Dejonghe P, Sadzot B, Van Rijckevorsel K, Schmedding E. Opinion of Belgian neurologists on antiepileptic drugs: Belgian Study on Epilepsy Treatment (BESET). Acta Neurol Scand 2007;115:97-103.

64. Maguire MJ, Hemming K, Hutton IL, Marson AG. Overwhelming heterogeneity in systematic reviews of observational anti-epileptic studies. Epilepsy Res 2008;80:201-212.

65. Hwang SD. Meta-analysis using R. 2nd ed. Seoul; Hakjisa; 2016.

66. Zhou C, Jiang R, Li G, Shao M, Chen C, Chen G, et al. Efficacy and tolerability of second and third generation anti-epileptic drugs in refractory epilepsy: a network meta-analysis. Sci Rep 2017;7:2535.

67. Zhao T, Feng X, Liu J, Gao J, Zhou C. Evaluate the efficacy and safety of anti-epileptic medications for partial seizures of epilepsy: a network meta-analysis. J Cell Biochem 2017;118:2850-2864.

68. Hilton EJ, Hosking SL, Betts T. The effect of antiepileptic drugs on visual performance. Seizure 2004;13:113-128.